CoChat
Sign Up
Cited by 62

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Constitutive α- and β-secretase cleavages of the amyloid precursor protein are partially coupled in neurons, but not in frequently used cell lines

Colombo, Alessio, Wang, Huanhuan, Kuhn, Peer-Hendrik, Page, Richard, Kremmer, Elisabeth, Dempsey, Peter J., Crawford, Howard C., Lichtenthaler, Stefan F.·2013·Neurobiology of Disease
DOI 10.1016/j.nbd.2012.08.011PMC PMC4310234
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.nbd.2012.08.011

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 52

  1. Ahmad, 2006, Cleavage of amyloid-beta precursor protein (APP) by membrane-type matrix metalloproteinases, J. Biochem., 139, 517, 10.1093/jb/mvj054 · DOI · Paper page
  2. Amtul, 2010, Neuroprotective mechanism conferred by 17beta-estradiol on the biochemical basis of Alzheimer's disease, Neuroscience, 169, 781, 10.1016/j.neuroscience.2010.05.031 · DOI
  3. Caccamo, 2006, Neuron, 49, 671, 10.1016/j.neuron.2006.01.020 · DOI · Paper page
  4. Colciaghi, 2002, [alpha]-Secretase ADAM10 as well as [alpha]APPs is reduced in platelets and CSF of Alzheimer disease patients, Mol. Med., 8, 67, 10.1007/BF03402076 · DOI
  5. Colombo, 2007, The TAT-JNK inhibitor peptide interferes with beta amyloid protein stability, Cell Death Differ., 14, 1845, 10.1038/sj.cdd.4402202 · DOI
  6. Colombo, 2009, JNK regulates APP cleavage and degradation in a model of Alzheimer's disease, Neurobiol. Dis., 33, 518, 10.1016/j.nbd.2008.12.014 · DOI
  7. Crawford, 2009, ADAM10 as a therapeutic target for cancer and inflammation, Curr. Pharm. Des., 15, 2288, 10.2174/138161209788682442 · DOI
  8. Darlak, 1990, Thiol-based inhibitors of mammalian collagenase. Substituted amide and peptide derivatives of the leucine analogue, 2-[(R, S)-mercaptomethyl]-4-methylpentanoic acid, J. Biol. Chem., 265, 5199, 10.1016/S0021-9258(19)34106-7 · DOI
  9. De Strooper, 1998, Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein, Nature, 391, 387, 10.1038/34910 · DOI · Paper page
  10. Donmez, 2010, SIRT1 suppresses beta-amyloid production by activating the alpha-secretase gene ADAM10, Cell, 142, 320, 10.1016/j.cell.2010.06.020 · DOI
  11. Encinas, 2000, Sequential treatment of SH-SY5Y cells with retinoic acid and brain-derived neurotrophic factor gives rise to fully differentiated, neurotrophic factor-dependent, human neuron-like cells, J. Neurochem., 75, 991, 10.1046/j.1471-4159.2000.0750991.x · DOI
  12. Endres, 2005, Shedding of the amyloid precursor protein-like protein APLP2 by disintegrin-metalloproteinases, FEBS J., 272, 5808, 10.1111/j.1742-4658.2005.04976.x · DOI
  13. Fahrenholz, 2007, Alpha-secretase as a therapeutic target, Curr. Alzheimer Res., 4, 412, 10.2174/156720507781788837 · DOI
  14. Fu, 2009, Eur. J. Pharmacol., 623, 14, 10.1016/j.ejphar.2009.09.013 · DOI
  15. Furukawa, 1996, Increased activity-regulating and neuroprotective efficacy of alpha-secretase-derived secreted amyloid precursor protein conferred by a C-terminal heparin-binding domain, J. Neurochem., 67, 1882, 10.1046/j.1471-4159.1996.67051882.x · DOI
  16. Gibb, 2010, ADAM10 is essential for Notch2-dependent marginal zone B cell development and CD23 cleavage in vivo, J. Exp. Med., 207, 623, 10.1084/jem.20091990 · DOI
  17. Haass, 2007, Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide, Nat. Rev. Mol. Cell Biol., 8, 101, 10.1038/nrm2101 · DOI · Paper page
  18. Hardy, 2002, The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics, Science, 297, 353, 10.1126/science.1072994 · DOI · Paper page
  19. Hartmann, 2002, The disintegrin/metalloprotease ADAM 10 is essential for Notch signalling but not for alpha-secretase activity in fibroblasts, Hum. Mol. Genet., 11, 2615, 10.1093/hmg/11.21.2615 · DOI
  20. Hogl, 2011, Determination of the proteolytic cleavage sites of the amyloid precursor-like protein 2 by the proteases ADAM10, BACE1 and γ-secretase, PLoS One, 6, e21337, 10.1371/journal.pone.0021337 · DOI
  21. Holback, 2008, PI3-K- and PKC-dependent up-regulation of APP processing enzymes by retinoic acid, Biochem. Biophys. Res. Commun., 365, 298, 10.1016/j.bbrc.2007.10.167 · DOI
  22. Horikoshi, 2004, Development of Abeta terminal end-specific antibodies and sensitive ELISA for Abeta variant, Biochem. Biophys. Res. Commun., 319, 733, 10.1016/j.bbrc.2004.05.051 · DOI
  23. Hung, 1993, Activation of protein kinase C inhibits cellular production of the amyloid beta-protein, J. Biol. Chem., 268, 22959, 10.1016/S0021-9258(19)49409-X · DOI
  24. Jefferson, 2011, Metalloprotease meprin beta generates nontoxic N-terminal amyloid precursor protein fragments in vivo, J. Biol. Chem., 286, 27741, 10.1074/jbc.M111.252718 · DOI · Paper page
  25. Jorissen, 2010, The disintegrin/metalloproteinase ADAM10 is essential for the establishment of the brain cortex, J. Neurosci., 30, 4833, 10.1523/JNEUROSCI.5221-09.2010 · DOI · Paper page
  26. Kim, 2009, Potential late-onset Alzheimer's disease-associated mutations in the ADAM10 gene attenuate {alpha}-secretase activity, Hum. Mol. Genet., 18, 3987, 10.1093/hmg/ddp323 · DOI · Paper page
  27. Kim, 2008, Effects of TNFalpha-converting enzyme inhibition on amyloid beta production and APP processing in vitro and in vivo, J. Neurosci., 28, 12052, 10.1523/JNEUROSCI.2913-08.2008 · DOI
  28. Kruse, 2004, Human meprin alpha and beta homo-oligomers: cleavage of basement membrane proteins and sensitivity to metalloprotease inhibitors, Biochem. J., 378, 383, 10.1042/bj20031163 · DOI
  29. Leissring, 2010, Designed inhibitors of insulin-degrading enzyme regulate the catabolism and activity of insulin, PLoS One, 5, e10504, 10.1371/journal.pone.0010504 · DOI
  30. Liao, 2010, Degradation of soluble and fibrillar amyloid beta-protein by matrix metalloproteinase (MT1-MMP) in vitro, Biochemistry, 49, 1127, 10.1021/bi901994d · DOI · Paper page
  31. Lichtenthaler, 2003, The cell adhesion protein P-selectin glycoprotein ligand-1 is a substrate for the aspartyl protease BACE1, J. Biol. Chem., 278, 48713, 10.1074/jbc.M303861200 · DOI · Paper page
  32. Lichtenthaler, 2011, Alpha-secretase in Alzheimer's disease: molecular identity, regulation and therapeutic potential, J. Neurochem., 116, 10, 10.1111/j.1471-4159.2010.07081.x · DOI
  33. Lichtenthaler, 2011, Alpha-secretase cleavage of the amyloid precursor protein: proteolysis regulated by signaling pathways and protein trafficking, Curr. Alzheimer Res., 9, 165, 10.2174/156720512799361655 · DOI · Paper page
  34. Marcello, 2007, Synapse-associated protein-97 mediates alpha-secretase ADAM10 trafficking and promotes its activity, J. Neurosci., 27, 1682, 10.1523/JNEUROSCI.3439-06.2007 · DOI
  35. Marcotte, 1999, Evaluation of the inhibition of other metalloproteinases by matrix metalloproteinase inhibitors, J. Enzyme Inhib., 14, 425, 10.3109/14756369909030333 · DOI
  36. May, 2011, Robust central reduction of amyloid-β in humans with an orally available, non-peptidic β-secretase inhibitor, J. Neurosci., 31, 16507, 10.1523/JNEUROSCI.3647-11.2011 · DOI · Paper page
  37. Meziane, 1998, Memory-enhancing effects of secreted forms of the beta-amyloid precursor protein in normal and amnestic mice, Proc. Natl. Acad. Sci. U. S. A., 95, 12683, 10.1073/pnas.95.21.12683 · DOI
  38. Miners, 2008, Abeta-degrading enzymes in Alzheimer's disease, Brain Pathol., 18, 240, 10.1111/j.1750-3639.2008.00132.x · DOI
  39. Mitterreiter, 2010, Bepridil and amiodarone simultaneously target the Alzheimer's disease beta- and gamma-secretase via distinct mechanisms, J. Neurosci., 30, 8974, 10.1523/JNEUROSCI.1199-10.2010 · DOI
  40. Nitsch, 1992, Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors, Science, 258, 304, 10.1126/science.1411529 · DOI · Paper page
  41. Postina, 2004, A disintegrin-metalloproteinase prevents amyloid plaque formation and hippocampal defects in an Alzheimer disease mouse model, J. Clin. Invest., 113, 1456, 10.1172/JCI20864 · DOI · Paper page
  42. Saftig, 2011, The “a disintegrin and metalloproteases” ADAM10 and ADAM17: novel drug targets with therapeutic potential?, Eur. J. Cell Biol., 90, 527, 10.1016/j.ejcb.2010.11.005 · DOI
  43. Saghatelian, 2004, Activity-based probes for the proteomic profiling of metalloproteases, Proc. Natl. Acad. Sci. U. S. A., 101, 10000, 10.1073/pnas.0402784101 · DOI
  44. Sala Frigerio, 2010, beta-Secretase cleavage is not required for generation of the intracellular C-terminal domain of the amyloid precursor family of proteins, FEBS J., 277, 1503, 10.1111/j.1742-4658.2010.07579.x · DOI
  45. Skovronsky, 2000, Protein kinase C-dependent alpha-secretase competes with beta-secretase for cleavage of amyloid-beta precursor protein in the trans-golgi network, J. Biol. Chem., 275, 2568, 10.1074/jbc.275.4.2568 · DOI
  46. Stachel, 2004, Structure-based design of potent and selective cell-permeable inhibitors of human beta-secretase (BACE-1), J. Med. Chem., 47, 6447, 10.1021/jm049379g · DOI · Paper page
  47. Stein, 2004, Neutralization of transthyretin reverses the neuroprotective effects of secreted amyloid precursor protein (APP) in APPSW mice resulting in tau phosphorylation and loss of hippocampal neurons: support for the amyloid hypothesis, J. Neurosci., 24, 7707, 10.1523/JNEUROSCI.2211-04.2004 · DOI
  48. Tachida, 2008, Interleukin-1 beta up-regulates TACE to enhance alpha-cleavage of APP in neurons: resulting decrease in Abeta production, J. Neurochem., 104, 1387, 10.1111/j.1471-4159.2007.05127.x · DOI · Paper page
  49. Vassar, 1999, Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE, Science, 286, 735, 10.1126/science.286.5440.735 · DOI · Paper page
  50. Willem, 2004, beta-site amyloid precursor protein cleaving enzyme 1 increases amyloid deposition in brain parenchyma but reduces cerebrovascular amyloid angiopathy in aging BACE×APP[V717I] double-transgenic mice, Am. J. Pathol., 165, 1621, 10.1016/S0002-9440(10)63419-0 · DOI
  51. Yin, 2006, Matrix metalloproteinases expressed by astrocytes mediate extracellular amyloid-beta peptide catabolism, J. Neurosci., 26, 10939, 10.1523/JNEUROSCI.2085-06.2006 · DOI · Paper page
  52. Zhao, 2007, Beta-site amyloid precursor protein cleaving enzyme 1 levels become elevated in neurons around amyloid plaques: implications for Alzheimer's disease pathogenesis, J. Neurosci., 27, 3639, 10.1523/JNEUROSCI.4396-06.2007 · DOI · Paper page

Cited by

Sorted by citations

Metadata

Authors
Colombo, A., Wang, H., Kuhn, P.-H., Page, R., Kremmer, E., Dempsey, P. J., Crawford, H. C., & Lichtenthaler, S. F.
Venue
Neurobiology of Disease
Publisher
Elsevier BV
Published
2013-01
Volume
49
Pages
137-147
ISSN
0969-9961
DOI
10.1016/j.nbd.2012.08.011
PMC
PMC4310234
Cited by
62
References
3
Language
en
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Funders
  • Deutsche Forschungsgemeinschaft (SFB596 project B12)
  • competence network degenerative dementias (BMBF) (project Z2)
  • Chinese Scholarship Council

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review